DEXCOM INC (DXCM)
Data as of , from SEC Form 4 filings.
See up to 3 months of DXCM. The 7-day demo opens the 1M and 3M ranges and puts DXCM on your watchlist.
Start 7-day demoLatest DXCM insider trades
About DEXCOM INC (DXCM)
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
- SAN DIEGO, CA
- 11,100
- 2005
- Nasdaq
DXCM Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 14 | 78,781 | $6.60M |
| Grant or award | 1 | 5,841 | |
| Tax withholding / forfeiture | 4 | 5,804 | |
DXCM insider transactions (Form 4)
4494 Form 4 filings on record, the earliest from Nov 18, 2024, newest first. Filing history page 3 of 3.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jacob Steven Leach - Officer | Open-market purchase | Common Stock | 15,700 | $54.98 footnote F1 | $863K | |
| Jacob Steven Leach - Officer | Open-market purchase | Common Stock | 2,500 | $55.43 footnote F2 | $139K | |
| ||||||
| Richard Alexander Collins - Director | Open-market sale | Common Stock | 3,948 footnote F1 | $55.17 | $218K | |
| ||||||
| Euan A. Ashley - Director | Grant or award | Common Stock | 7,166 footnote F1 | $0.00 | - | |
| ||||||
 Kyle Malady - Director | Open-market sale | Common Stock | 667 | $80.86 | $54K | |
| Sadie Stern - Officer | Open-market sale | Common Stock | 1,466 | $80.00 | $117K | |
 Jereme M. Sylvain - Officer | Open-market sale | Common Stock | 4,824 | $74.17 | $358K | |
 Michael Jon Brown - Officer | Open-market sale | Common Stock | 500 | $80.29 | $40K | |
 Mark G. Foletta - Director | Open-market sale | Common Stock | 2,555 | $81.02 | $207K | |
| Mark G. Foletta - Director | Open-market sale | Common Stock | 195 | $81.54 | $16K | |
| Sadie Stern - Officer | Open-market sale | Common Stock | 1,466 | $88.99 | $130K | |
| Mark G. Foletta - Director | Open-market sale | Common Stock | 2,742 | $85.17 | $234K | |
| Mark G. Foletta - Director | Open-market sale | Common Stock | 8 | $86.03 | $688 | |
| Michael Jon Brown - Officer | Open-market sale | Common Stock | 500 | $86.03 | $43K | |
| Sadie Stern - Officer | Open-market sale | Common Stock | 1,466 | $85.06 | $125K | |
| Nicholas Augustinos - Director | Open-market sale | Common Stock | 2,618 | $81.69 | $214K | |
| Nicholas Augustinos - Director | Open-market sale | Common Stock | 3,672 | $82.80 | $304K | |
| Mark G. Foletta - Director | Open-market sale | Common Stock | 2,750 | $83.13 | $229K | |
| Michael Jon Brown - Officer | Open-market sale | Common Stock | 500 | $82.80 | $41K | |
| Sadie Stern - Officer | Open-market sale | Common Stock | 6,184 | $85.11 | $526K | |
| Michael Jon Brown - Officer | Open-market sale | Common Stock | 10,000 | $84.28 | $843K | |
| Jon Coleman - Officer | Grant or award | Common Stock | 68,738 | $0.00 | - | |
 Rimma Driscoll - Director | Grant or award | Common Stock | 5,074 | $0.00 | - | |
| Kyle Malady - Director | Grant or award | Common Stock | 5,192 | $0.00 | - | |
| Bridgette P. Heller - Director | Grant or award | Common Stock | 5,046 | $0.00 | - | |
| Karen M. Dahut - Director | Gift | Common Stock | 2,613 | $0.00 | - | |
| Karen M. Dahut - Director | Gift | Common Stock | 2,613 | $0.00 | - | |
| Nicholas Augustinos - Director | Gift | Common Stock | 2,618 | $0.00 | - | |
| Nicholas Augustinos - Director | Gift | Common Stock | 2,618 | $0.00 | - | |
| Nicholas Augustinos - Director | Grant or award | Common Stock | 5,046 | $0.00 | - | |
| Mark G. Foletta - Director | Gift | Common Stock | 2,973 | $0.00 | - | |
| Mark G. Foletta - Director | Gift | Common Stock | 2,973 | $0.00 | - | |
| Mark G. Foletta - Director | Grant or award | Common Stock | 5,731 | $0.00 | - | |
| Richard Alexander Collins - Director | Gift | Common Stock | 2,632 | $0.00 | - | |
| Richard Alexander Collins - Director | Gift | Common Stock | 2,632 | $0.00 | - | |
| Richard Alexander Collins - Director | Grant or award | Common Stock | 5,074 | $0.00 | - | |
| Steven R. Altman - Director | Gift | Common Stock | 2,613 | $0.00 | - | |
| Steven R. Altman - Director | Gift | Common Stock | 2,613 | $0.00 | - | |
| Steven R. Altman - Director | Grant or award | Common Stock | 5,037 | $0.00 | - | |
| Eric Topol - Director | Gift | Common Stock | 2,618 | $0.00 | - | |
| Eric Topol - Director | Gift | Common Stock | 2,618 | $0.00 | - | |
| Renee D. Gala - Director | Grant or award | Common Stock | 1,161 | $0.00 | - | |
| Sadie Stern - Officer | Open-market sale | Common Stock | 424 | $76.87 | $33K | |
| Jereme M. Sylvain - Officer | Open-market sale | Common Stock | 744 | $76.87 | $57K | |
See every DXCM filing on record
These pages show the latest 90 of 94 Form 4 filings on record. The 7-day demo shows all 94, and sign-up brings you back to this table.
Recent DXCM Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| MICHAEL BROWN | Officer | 1,700 | $145K | View on EDGAR | |
| SADIE STERN | Officer | 2,565 |
DXCM insider trading FAQ
What is the latest insider trade for DXCM?
DEXCOM INC (DXCM) had 16 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for DXCM runs to 94 Form 4 filings, the earliest from 2024-11-18. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DXCM stock?
No insider purchases of DXCM were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling DXCM stock?
14 insider sales of DXCM were filed in the last 90 days, totaling $6.60M.
Where can I see DXCM SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DXCM Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Sadie Stern view on EDGAR
- - Nicholas Augustinos view on EDGAR
- - Michael Jon Brown view on EDGAR
- - Jereme M. Sylvain view on EDGAR
- - Glenn S. Boehnlein view on EDGAR
- - Sadie Stern view on EDGAR
- - Jacob Steven Leach view on EDGAR
- - Jereme M. Sylvain view on EDGAR
- - Michael Jon Brown view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where DXCM's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DXCM with a 7-day demo
- DXCM on your watchlist
- Every DXCM Form 4 filing on record
- Up to 3 months of DXCM price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
